Analyst Greg McLeish gives the company a buy rating and a 12-month target price of $4.50, a premium of 228% to the $1.37 price on December 18th, the day the report was issued.
research nlv organics cannabis production cannabis cultivation medical cultivation medical production buy recommendation national capital markets greg mcleish ken villazor recreational cannabis nevada mackie research $fone.c